Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 21:16:A2.
doi: 10.18332/tid/93305. eCollection 2018.

Study Protocol of European Regulatory Science on Tobacco (EUREST-PLUS): Policy implementation to reduce lung disease

Constantine I Vardavas  1   2 , Nicolas Bécuwe  3 , Tibor Demjén  4 , Esteve Fernández  5   6 , Ann McNeill  7 , Ute Mons  8 , Yannis Tountas  9 , Antigona C Trofor  10   11 , Aristides Tsatsakis  2 , Gernot Rohde  12 , Marc Willemsen  13 , Krzysztof Przewozniak  14 , Witold A Zatonski  14 , Geoffrey T Fong  15   16 ; EUREST-PLUS consortium
Affiliations

Study Protocol of European Regulatory Science on Tobacco (EUREST-PLUS): Policy implementation to reduce lung disease

Constantine I Vardavas et al. Tob Induc Dis. .

Abstract

Efforts to mitigate the devastation of tobacco-attributable morbidity and mortality in the European Union (EU) are founded on its newly adopted Tobacco Products Directive (TPD) along with the first-ever health treaty, the WHO Framework Convention on Tobacco Control (FCTC). The aim of this Horizon 2020 Project entitled European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Disease (EURESTPLUS) is to monitor and evaluate the impact of the implementation of the TPD across the EU, within the context of WHO FCTC ratification. To address this aim, EUREST-PLUS consists of four objectives: 1) To create a cohort study of 6000 adult smokers in six EU MS (Germany, Greece, Hungary, Poland, Romania, Spain) within a pre-TID vs post-TPD implementation study design; 2) To conduct secondary dataset analyses of the Special Eurobarometer on Tobacco Survey (SETS); 3) To document changes in e-cigarette product parameters (technical design, labelling/packaging and chemical composition) pre-TID vs post-TPD; and 4) To enhance innovative joint research collaborations on chronic non-communicable diseases. Through this methodological approach, EUREST-PLUS is designed to generate strong inferences about the effectiveness of tobacco control policies, as well as to elucidate the mechanisms and factors by which policy implementation translates to population impact. Findings from EUREST-PLUS have potential global implications for the implementation of innovative tobacco control policies and its impact on the prevention of lung diseases.

Keywords: WHO FCTC; policy implementation; regulatory science; tobacco control; tobacco products directive.

PubMed Disclaimer

Conflict of interest statement

C. I. Vardavas reports that he is the Strategic Development Editor of TID and that there are no conflicts of interest with this current work. G. Rohde reports personal fees from Pfizer, Boehringer Ingelheim, Solvay, GSK, Essex Pharma, MSD, Grifols, Chiesi, Vertex, Roche and Novartis for lectures including service on speakers bureaus outside the submitted work and/or consultancy during advisory board meeting and personal fees from GSK for travel accommodations/meeting expenses, outside the submitted work. K. Przewoźniak reports grants and personal fees from Polish League Against Cancer, outside the submitted work. The rest of the authors have also completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work.

References

    1. World Health Organization . Who Report on the Global Tobacco Epidemic, 2017. 2017. pp. 1–263.
    1. World Health Organization . The European Tobacco Control Report 2007. Copenhagen, Denmark: WHO Regional Office for Europe; 2007. p. 16.
    1. Peto R, Lopez AD, Boreham J, Thun MJ. Mortality from smoking in developed countries 1950-2000. 2nd ed. Geneva; Switzerland: International Union Against Cancer (UICC; 2006.
    1. Tsalapati K, Vardavas CI, Athanasakis K, et al. Going up in ashes? Smoking-attributable morbidity, hospital admissions and expenditure in Greece. Eur J Public Health. 2014;24(3):477–479. doi: 10.1093/eurpub/cku040. - DOI - PubMed
    1. Max W. The Financial Impact of Smoking on Health-Related Costs: A Review of the Literature. Am J Heal Promot. 2001;15(5):321–331. doi: 10.4278/0890-1171-15.5.321. - DOI - PubMed